Operations and supply chain executive with more than 20 years of experience spanning GMP manufacturing, global clinical and commercial supply, and gene therapy launch executionFormer VP of Global Supply Chain and interim Chief Technical Officer at AveXis, where he built and led the global supply chain organization through the launch of Zolgensma® across more than 30 countriesAppointment strengthens manufacturing and supply chain leadership as Nanoscope advances lead product MOGENRY™ through regulatory review toward potential global commercialization

DALLAS, Oct. 14, 2026 /PRNewswire/ — Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced the appointment of Troy Short as Senior Vice President, Manufacturing and Supply Chain. In this role, Short will lead Nanoscope’s GMP manufacturing, commercial supply, and global distribution strategy as the company advances toward the potential approval and launch of MOGENRY™ (sonpiretigene isteparvovec; MCO-010).

Mr. Short brings more than two decades of operations and supply chain leadership across the pharmaceutical and gene therapy industries, with particular depth in building the manufacturing and distribution capabilities required to bring genetic medicines to patients. He previously served as Vice President of Global Supply Chain at AveXis, Inc., where he built and led the global commercial supply chain organization through the launch of Zolgensma®, scaling distribution globally, including the design of the specialized cold-chain model required for patient-specific delivery. He negotiated supply agreements, managed raw material sourcing, led the enterprise resource planning system implementation, and played a leadership role in FDA licensure and commercial readiness. Following the acquisition of AveXis by Novartis, he served as interim Chief Technical Officer during the transition.

Mr. Short subsequently served as Senior Vice President of Manufacturing and Supply Chain at Jaguar Gene Therapy, where he built Jaguar’s CMC and supply chain organization, internalized process and analytical development, and directed the design of their GMP manufacturing facility. He later served as Chief Operating Officer of Advanced Medicine Partners, leading the design and startup of their GMP facility. Most recently, through his firm GTxConsulting, he has advised biotechnology companies and investment firms on CMC strategy, as well as supply chain and BLA readiness for gene therapies and other advanced modalities. Earlier in his career, Mr. Short spent 11 years at Hospira, a Pfizer company, as Director of Supply Chain for sterile pharmaceutical manufacturing.

“Troy has done what very few people in our industry have done: built and run the supply chain that delivered an approved AAV gene therapy to patients around the world,” said Sulagna Bhattacharya, Co-Founder and Chief Executive Officer of Nanoscope Therapeutics. “A one-time intravitreal therapy manufactured in the U.S. has to reach every patient who needs it, at quality, without interruption. That capability is built years in advance, and Troy knows exactly how to execute. His arrival at this stage reflects how seriously we are taking our preparation for launch.”

Nanoscope continues to build clinical, regulatory, scaled-up manufacturing, and commercial-preparation momentum in support of MOGENRY for inherited retinal dystrophies (IRDs). The U.S. Food and Drug Administration (FDA) has accepted and filed the company’s Biologics License Application (BLA) for MOGENRY for the treatment of retinitis pigmentosa (RP) with severe vision loss. The BLA is presently under FDA review. A Japan New Drug Application (JNDA) for MOGENRY is also currently under PMDA review for IRDs. These milestones reflect the company’s expanding international regulatory pathway as it advances commercialization planning across key global markets.

“MOGENRY is designed to work regardless of the gene behind a patient’s vision loss. My job is to make sure it reaches them,” said Short. “My focus will be on strengthening our manufacturing partnerships, building a resilient commercial supply chain, and making sure patients and their physicians can count on product availability upon its potential approval.” 

About Inherited Retinal Dystrophies
Inherited retinal dystrophies (IRDs) are a genetically diverse group of rare disorders, caused by mutations in more than 250 genes, in which progressive loss of photoreceptor cells leads to impaired vision and, in most cases, complete blindness. IRDs include retinitis pigmentosa, the most common IRD, as well as Stargardt disease, cone-rod dystrophies, and Leber congenital amaurosis, among others. Because gene-specific therapies address only a single genetic cause, the vast majority of patients with IRDs have no approved treatment option.

About MOGENRY (sonpiretigene isteparvovec; MCO-010)
Nanoscope’s multi-characteristic opsin (MCO) technology utilizes a proprietary genetically engineered synthetic opsin to enable optimized performance in terms of high light sensitivity across a broad spectrum and fast kinetics. After Nanoscope’s Co-Founder, President, and Chief Scientific Officer, Samarendra Mohanty, envisioned and invented the technology, his team spent more than a decade evaluating its performance across multiple animal models and human diseases. MOGENRY is an investigational, one-time, in-office, intravitreal optogenetic gene therapy built on Nanoscope’s MCO platform. By delivering a multi-characteristic opsin gene to the highly dense bipolar retinal cells, MOGENRY makes these surviving cells directly light-sensitive, enabling them to utilize the remaining visual circuitry following photoreceptor loss. MOGENRY does not require genetic testing, invasive surgery, or repeat dosing, and is designed for administration within existing retina office workflows.

About Nanoscope Therapeutics
Nanoscope Therapeutics is developing disease-agnostic, vision-restoring optogenetic therapy for millions of patients blinded by retinal degenerative diseases. Following positive results from the RESTORE Phase 2b/3 multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the FDA has accepted and filed the company’s BLA for MOGENRY, and the PMDA has accepted for priority review the company’s Japan new drug application (JNDA) for MOGENRY for the treatment of IRDs. If approved, MOGENRY has the potential to become the standard of care for patients with RP and other IRDs, administered as a one-time, in-office injection without the need for genetic testing. The company has also shown promising results in the STARLIGHT Phase 2 clinical trial (NCT05417126) of MCO-010 in Stargardt disease (SD) and plans to initiate a Phase 3 registrational trial in 2026. MCO-010 has received FDA Fast Track and Orphan Drug designations for both RP and SD, along with Regenerative Medicine Advanced Therapy (RMAT) designation for SD, and European Medicines Agency (EMA) Orphan designations covering non-syndromic and syndromic rod- and cone-dominant dystrophies, as well as macular dystrophies. MCO-010 has also received Sakigake and Orphan designations for IRDs in Japan and an Orphan designation for IRDs in Saudi Arabia. A Phase 2 program for MCO in geographic atrophy is expected to start in 2026, and other investigational new drug (IND)-ready programs include Leber congenital amaurosis (LCA). Learn more at NanosTherapeutics.com and follow @NSTherapeutics on X and on LinkedIn. 

Contact:
Nanoscope Therapeutics Inc.
+1 (817) 857-1186
PR@nanostherapeutics.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/nanoscope-therapeutics-appoints-gene-therapy-operations-leader-troy-short-as-senior-vice-president-manufacturing-and-supply-chain-302908069.html

SOURCE Nanoscope Therapeutics

MCLEAN, Va., Oct. 14, 2026 /CNW/ — Iridium Communications Inc. (Nasdaq: IRDM), a leading provider of global voice, data, aircraft surveillance, and positioning, navigation, and timing (PNT) satellite services, today announced that Altair Semiconductor, a world leader in cellular IoT chips, is integrating Iridium NTN Direct℠ capability into Altair’s ALT1350 and next-generation ALT1550 IoT chipset platforms. With terrestrial cellular IoT and Iridium satellite connectivity on a single chipset, device manufacturers, module makers and mobile network operators (MNOs) will be able to extend IoT connectivity beyond the reach of terrestrial networks through the Iridium satellite network, without adding a separate satellite modem to their designs.

The partnership combines Altair’s cellular IoT chipset technology, among the most highly integrated low-power connectivity solutions available, with Iridium’s 3GPP standards-based non-terrestrial network (NTN) service, giving device manufacturers another chipset option for products that need connectivity beyond terrestrial cellular coverage. With the ultra-low-power ALT1350, these connectivity requirements can include asset tracking, logistics, smart metering and utilities, agriculture, vehicle telematics, industrial monitoring and remote infrastructure. With the ALT1550, these capabilities extend to a new generation of AI-powered 5G eRedCap devices, such as smart glasses, AI assistants and other wearables, that need to stay connected wherever they go.

“Altair has deep experience developing highly integrated, low-power IoT solutions, and we’re excited to work together to extend their reach with Iridium’s truly global satellite network,” said Tim Last, executive vice president, Iridium. “As a market leader in satellite IoT, Iridium is offering device manufacturers a powerful new way to develop connected products. Integrating Iridium NTN Direct into Altair’s chipsets will enable solutions and applications that require reliable, low-power connectivity beyond the limits of terrestrial networks.”

“Adding Iridium NTN Direct to our ultra-low-power LTE-M/NB-IoT ALT1350 and 5G eRedCap ALT1550 chipsets reflects our commitment to giving customers greater flexibility in how and where their IoT devices connect,” said Dima Feldman, VP Product Management and Marketing, Altair Semiconductor. “With Iridium’s truly global LEO satellite connectivity alongside terrestrial cellular, device manufacturers can more easily develop solutions that will reliably work anywhere they’re deployed.”

Iridium NTN Direct leverages Iridium’s fully operational, LEO satellite constellation and globally coordinated L-band spectrum to extend standards-based connectivity beyond terrestrial networks. The service is designed to support NB-IoT and direct-to-device (D2D) applications using compatible 3GPP standards-based chipsets, providing MNOs, chipset manufacturers and device makers with a path to extend connectivity through the Iridium satellite network.

Altair joins a growing ecosystem of partners bringing the Iridium NTN Direct service to market. A combination of chipmakers, module manufacturers, OEMs, device makers, and IoT developers is leading the next generation of NTN-cellular integration with Iridium NTN Direct.

For more information about Iridium NTN Direct, visit www.iridium.com/ntn-direct

About Iridium Communications Inc.

Iridium Communications Inc. (Nasdaq: IRDM) operates the world’s only truly global mobile satellite network. It serves as a platform for innovation, enabling voice, data, and messaging, positioning, navigation, and timing (PNT), and aircraft surveillance services anywhere on Earth. Through its satellite constellation and integrated capabilities like Aireon, the world’s only space-based air traffic surveillance system, Iridium delivers services that support safety-focused operations across aviation, maritime, government, industrial, and consumer markets. The company is a leader in satellite Internet of Things (IoT) connectivity and is advancing direct-to-device (D2D) communications based on open standards to expand access to satellite services.

Headquartered in McLean, Virginia, Iridium innovates through an ecosystem of more than 500 technology and distribution partners, serving millions of customers worldwide. For more information visit www.iridium.com.

Forward-Looking Statements Disclosure

Statements in this press release that are not purely historical facts may constitute forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. The company has based these statements on its current expectations and the information currently available to us. Forward-looking statements in this press release include statements regarding the capabilities, benefits and availability of the Iridium NTN Direct service. Forward-looking statements can be identified by the words “anticipates,” “may,” “can,” “believes,” “expects,” “projects,” “intends,” “likely,” “will,” “to be” and other expressions that are predictions or indicate future events, trends or prospects. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Iridium to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, uncertainties regarding the timing of commercial availability of the Iridium NTN Direct service, the company’s ability to maintain the health, capacity and content of its satellite constellation, general industry and economic conditions, and competitive, legal, governmental and technological factors. Other factors that could cause actual results to differ materially from those indicated by the forward-looking statements include those factors listed under the caption “Risk Factors” in the company’s Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) on February 12, 2026, and the company’s Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on July 22, 2026, as well as other filings Iridium makes with the SEC from time to time. There is no assurance that Iridium’s expectations will be realized. If one or more of these risks or uncertainties materialize, or if Iridium’s underlying assumptions prove incorrect, actual results may vary materially from those expected, estimated or projected. Iridium’s forward-looking statements speak only as of the date of this press release, and Iridium undertakes no obligation to update or revise any forward-looking statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/altair-semiconductor-integrates-iridium-ntn-direct-into-alt1350-and-alt1550-cellular-iot-chipsets-302907606.html

SOURCE Iridium Communications Inc.

The combination brings together deep expertise in liquid cooling, mechanical and electrical (M&E) engineering, ODM manufacturing, connectivity and facilities management (FM), giving data centre operators worldwide a single partner from design through to operation.

LONDON, Oct. 14, 2026 /PRNewswire/ — 3C, the liquid-cooling-led data centre infrastructure services company founded by former CoolIT Systems CEO Steve Walton, has merged with Datalec Precision Installations, the London-based data centre engineering specialist founded in 2012, to create 3C Datalec, a global platform that designs, builds and operates critical infrastructure for AI data centres.

Backed by new investment from Longbow Capital, S2G Investments, Apogem Capital and QIC, 3C Datalec will accelerate its international growth, invest in specialist talent and expand its technical capabilities as AI demand grows. Over the next 12 months, the company will hire 200 engineers and open new facilities in Warsaw, Poland; Calgary, Alberta; and Austin, Texas.

The combined business has approximately 1,000 team members and forecasts 2026 revenue to be over US$400 million, with offices and manufacturing facilities across Europe, the Middle East, Asia-Pacific and North America. It works with four of the five largest hyperscalers and over 25 colocation providers, alongside neoclouds and enterprise customers, with active projects in 16 countries totalling hundreds of megawatts (MW).

As AI workloads drive up compute density, power requirements and thermal complexity, 3C Datalec organises its capabilities into three pillars:

Create – design and engineering
Construct – liquid cooling, M&E, ODM manufacturing and connectivity installation
Care – commissioning, operations, maintenance and facilities management

“Rack densities have outgrown air, and liquid cooling is no longer optional,” said Steve Walton, CEO of 3C Datalec. “At CoolIT, we spent years preparing for this moment and became a global leader in liquid cooling. The hard part now is making cooling, power, construction and operations work as one system, while running at scale. We’re combining our liquid cooling expertise with Datalec’s engineering, manufacturing and FM capabilities, so customers have one partner from design to operation.”

The industry is running short of skilled data centre engineers, so 3C Datalec is training its own. Team members have access to apprenticeships, technical training and career development programs through the company’s internal university, and will share in its success through the Leadership & Employee Equity Program (LEEP). The goal: build the next generation of liquid cooling and critical infrastructure specialists.

“Datalec has always been a people-first business. We’ve grown by building strong relationships, delivering for our customers and creating a culture that people want to be part of,” said Danny Keeper, Group Director & Co-Founder of Datalec. “Finding a partner in 3C that genuinely shares those values was extremely important to us. This partnership allows us to grow globally while protecting the culture and identity that have been at the heart of Datalec since day one.”

“Our customers have trusted Datalec with their most critical sites for more than a decade, and we earn that trust on every project,” added Stuart Richmond, Group Director & Co-Founder of Datalec. “Joining 3C means we can now offer liquid cooling at global scale, but our commitment doesn’t change: the same teams, the same contacts and the same focus on getting it right for every customer.”

“AI is rewriting the requirements for data centre infrastructure and liquid cooling sits at the centre of that shift,” said Matthew Cunning, Director at Longbow Capital. “Steve helped build a category leader in liquid cooling and Datalec brings a proven delivery business with a loyal customer base. We’re backing 3C Datalec to become the partner of choice for AI-ready infrastructure.”

“The next phase of data centre investment will be shaped by both new development and the need to upgrade existing facilities for higher-density workloads,” said Bala Nagarajan, Managing Director at S2G Investments. “Datalec has built deep trust delivering complex projects in that environment, and 3C brings the experience and capabilities to extend those relationships into a broader set of services across the life of a facility.”

Datalec’s headquarters will remain in London, and its founding leadership team will continue in their executive roles within the enlarged group. Financial terms were not disclosed.

About 3C Datalec

3C Datalec designs, builds and operates critical infrastructure for AI and high-density data centres. Formed in 2026 through the combination of 3C, founded by former CoolIT Systems CEO Steve Walton, and Datalec Precision Installations, founded in London in 2012, the company brings liquid cooling, M&E engineering, ODM manufacturing, connectivity and facilities management together, built around Create • Construct • Care. With approximately 1,000 team members and active projects in 16 countries, 3C Datalec serves hyperscalers, colocation providers, neoclouds and enterprises across Europe, the Middle East, Asia-Pacific and North America. 3C Datalec is backed by Longbow Capital, S2G Investments, Apogem Capital, and QIC. For more information, visit www.datalecltd.com.

About S2G Investments

S2G Investments is a multi-asset investment firm focused on scaling durable, market-defining businesses across food & agriculture, energy, and oceans. We provide capital and value-added resources to companies commercializing solutions designed to improve efficiency, resilience, and long-term value across industries powering the global economy. Through fit-for-purpose financing and a systems-focused investment approach, S2G is committed to driving measurable, sustained outcomes with tailored solutions that span late-stage venture, growth equity, structured finance, and infrastructure. For more information about S2G, visit s2ginvestments.com or connect with us on LinkedIn.

About Longbow Capital

Longbow Capital is a Canadian investment manager focused on investing in energy, power, industrials, and technology. Since its founding in 1997, Longbow has been a long-term strategic partner and an engaged and effective shareholder in over 150 high-growth investments. Longbow’s investment track record, extensive relationship network, and deep understanding of how our energy system works enable us to source, evaluate, and invest in opportunities arising from some of the most significant societal and economic shifts underway today – decarbonization, digital infrastructure buildout, and deglobalization – where technology-driven change is reshaping markets and creating compelling investment opportunities.

About Apogem Capital

Apogem Capital is a leading private markets investor with 35 years of expertise across private credit and private equity in North America. As of June 30, 2026, the firm manages approximately $44 billion in assets.1 Apogem provides a comprehensive suite of solutions, including direct lending, private equity funds and co-investments, GP-led transactions and LP secondaries, GP stakes, and private real assets.

With a team of over 250 professionals, including more than 120 investment professionals, Apogem combines deep domain expertise with the stability and long-term perspective of its parent company, New York Life Insurance Company. Apogem Capital is a wholly owned subsidiary of New York Life through New York Life Investment Management Holdings, LLC. For more information, visit apogemcapital.com.

1 AUM is estimated and unaudited as of June 30, 2026, and includes non-discretionary and co-advised assets.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/3c-merges-with-datalec-to-create-us400m-revenue-liquid-cooling-and-data-centre-services-platform-302907919.html

SOURCE 3C Datalec